A major challenge in Orthopaedic surgery, trauma, and plastic surgery is regeneration of skeletal tissues. Current options are limited to biologically inactive space fillers or expensive recombinant proteins, peptides, and antibodies that are generally more costly to make and may include other challenges to clinical use. The best possible solution would be a small molecule capable of regenerating musculoskeletal tissues from scratch (bone, cartilage, ligament, tendon), with an acceptable safety and toxicity profile, and is inexpensive to manufacture. To date, no one else has developed small molecules with these key attributes. The market is wide open for such a transformational discovery.
Enter SkelRegen. SkelRegen, LLC is the first company to identify not one, but multiple small molecules that are osteoinductive and target different aspects of the musculoskeletal tissue formation pathway. These unique compounds have been shown to successfully block specific intracellular/extracellular inhibitors of BMPs, key regulators of bone and soft tissue growth. Blocking the inhibitors of BMP dramatically enhances the body’s own stem cells and growth factors that regenerate bone and soft tissue. Here’s the best part. First, all of these compounds are inexpensive to manufacture. Second, many have already been cleared by the FDA for other uses, which means they already have acceptable safety and toxicity profiles. It just doesn’t get any better for development.
The discoveries have already been made. The IP is ours. Provisional patents are in place. SkelRegen is now focused entirely on bringing these game-changing technologies to the bedside. Investment, partnering, and licensing opportunities abound as SkelRegen continues its development of our existing technologies and searches for additional disruptive technologies. We are actively engaged in developing products for healthcare companies working on spine, trauma, dental (OMF), orthopaedic, osteoporosis, and soft tissue reconstructive challenges. Our development approach takes into account the unique attributes in each of these market segments along with the reality of future healthcare economics. SkelRegen is now aligning itself with investors and partners by compound, segment, and stage of the product development process. Want to know more? Contact us now.
Interested in learning more? Contact us.